Idiopathic Giant-Cell Myocarditis ??? Natural History and Treatment, New England Journal of Medicine, vol.336, issue.26, pp.1860-1866, 1997. ,
DOI : 10.1056/NEJM199706263362603
Long-term outcome and its predictors in giant cell myocarditis, European Journal of Heart Failure, vol.165, issue.12, pp.1452-1460, 2016. ,
DOI : 10.1093/aje/kwk052
Diagnosis, Treatment, and Outcome of Giant-Cell Myocarditis in the Era of Combined Immunosuppression, Circulation: Heart Failure, vol.6, issue.1, pp.15-22, 2013. ,
DOI : 10.1161/CIRCHEARTFAILURE.112.969261
Usefulness of Immunosuppression for Giant Cell Myocarditis, The American Journal of Cardiology, vol.102, issue.11, pp.1535-1544, 2008. ,
DOI : 10.1016/j.amjcard.2008.07.041
Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome, The Journal of Heart and Lung Transplantation, vol.21, issue.6, pp.674-683, 2002. ,
DOI : 10.1016/S1053-2498(02)00379-0
Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis, The American Journal of Cardiology, vol.115, issue.12, pp.1733-1741, 2015. ,
DOI : 10.1016/j.amjcard.2015.03.023
Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes, Circulation, vol.83, issue.3, pp.953-61, 1991. ,
DOI : 10.1161/01.CIR.83.3.953
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Journal of Heart Failure, vol.37, issue.8, pp.2129-200, 2016. ,
DOI : 10.1016/j.jpainsymman.2007.12.015
Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock*, Critical Care Medicine, vol.36, issue.5, pp.1404-1415, 2008. ,
DOI : 10.1097/CCM.0b013e31816f7cf7
Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support*, Critical Care Medicine, vol.39, issue.5, pp.1029-1064, 2011. ,
DOI : 10.1097/CCM.0b013e31820ead45
APACHE II, Critical Care Medicine, vol.13, issue.10, pp.818-847, 1985. ,
DOI : 10.1097/00003246-198510000-00009
A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study, Jama, vol.270, pp.2957-63, 1993. ,
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure, Intensive Care Medicine, vol.21, issue.7, pp.707-717, 1996. ,
DOI : 10.1007/BF01726543
Postoperative Course and Hemodynamic Profile After the Arterial Switch Operation in Neonates and Infants : A Comparison of Low-Flow Cardiopulmonary Bypass and Circulatory Arrest, Circulation, vol.92, issue.8, pp.2226-2261, 1995. ,
DOI : 10.1161/01.CIR.92.8.2226
INTERMACS Profiles of Advanced Heart Failure: The Current Picture, The Journal of Heart and Lung Transplantation, vol.28, issue.6, pp.535-576, 2009. ,
DOI : 10.1016/j.healun.2009.02.015
Heart Transplantation in Giant Cell Myocarditis: Analysis of the United Network for Organ Sharing Registry, Journal of Cardiac Failure, vol.23, issue.7, pp.566-575, 2017. ,
DOI : 10.1016/j.cardfail.2017.04.015
Survival Outcomes of Patients with Giant Cell Myocarditis Bridged by Ventricular Assist Devices, ASAIO Journal, vol.46, issue.5, pp.46-569, 2000. ,
DOI : 10.1097/00002480-200009000-00011
Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes, Journal of Cardiac Failure, vol.22, issue.7, pp.583-588, 2016. ,
DOI : 10.1016/j.cardfail.2015.12.022
Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis, European Journal of Heart Failure, vol.4, issue.7 Suppl, pp.312-320, 2012. ,
DOI : 10.1161/CIRCHEARTFAILURE.110.958520
Mechanical assist and transplantation for treatment of giant cell myocarditis, Canadian Journal of Cardiology, vol.26, issue.2, pp.96-103, 2010. ,
DOI : 10.1016/S0828-282X(10)70011-8
Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days, Journal of Cardiovascular Medicine, vol.17, 2015. ,
DOI : 10.2459/JCM.0000000000000250
Recovery of giant-cell myocarditis using combined cytolytic immunosuppression and mechanical circulatory support, The Journal of Heart and Lung Transplantation, vol.33, issue.7, pp.769-71, 2014. ,
DOI : 10.1016/j.healun.2014.02.018
Recovery from Giant Cell Myocarditis with ECMO Support and Utilisation of Polyclonal Antithymocyte Globulin: A Case Report, The Thoracic and Cardiovascular Surgeon, vol.54, issue.4, pp.278-80, 2006. ,
DOI : 10.1055/s-2006-923803
An alternative immunosuppressive regimen to prolong transplant free survival in a patient with giant cell myocarditis, International Journal of Cardiology, vol.168, issue.1, pp.27-35, 2013. ,
DOI : 10.1016/j.ijcard.2013.05.078
Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy, The Journal of Heart and Lung Transplantation, vol.21, issue.7, pp.818-839, 2002. ,
DOI : 10.1016/S1053-2498(01)00396-5
Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis, The American Journal of Cardiology, vol.116, issue.3, pp.447-51, 2015. ,
DOI : 10.1016/j.amjcard.2015.04.040
Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis, Circulation, vol.136, issue.6, pp.529-574, 2017. ,
DOI : 10.1161/CIRCULATIONAHA.117.026386
Incidence, Risk Factors, and Outcome of Life-Threatening Ventricular Arrhythmias in Giant Cell Myocarditis, Circulation: Arrhythmia and Electrophysiology, vol.9, issue.12, 2016. ,
DOI : 10.1161/CIRCEP.116.004559
The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, Circulation, vol.116, issue.19, pp.2216-2249, 2007. ,
DOI : 10.1161/CIRCULATIONAHA.107.186093
Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis??in??Adult Patients: A 5-Year Multi-Institutional Experience, The Annals of Thoracic Surgery, vol.101, issue.3, pp.919-945, 2016. ,
DOI : 10.1016/j.athoracsur.2015.08.014
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, European Heart Journal, vol.321, issue.16, pp.2636-2684, 2013. ,
DOI : 10.1056/NEJM198910193211601
Management of fulminant myocarditis: A diagnosis in search of its etiology but with therapeutic options, Current Heart Failure Reports, vol.103, issue.18, pp.166-77, 2014. ,
DOI : 10.1161/01.CIR.103.18.2254
The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis, Journal of Cardiac Failure, vol.8, issue.2, pp.74-82, 2002. ,
DOI : 10.1054/jcaf.2002.32196
Contribution and Risks of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies: A Retrospective Study Over a 28-Year Period, Circulation, vol.128, issue.14, pp.1531-1572, 2013. ,
DOI : 10.1161/CIRCULATIONAHA.13.001414
The Changing Role for Endomyocardial Biopsy in the Diagnosis of Giant-Cell Myocarditis, Cardiology and Therapy, vol.6, issue.14, pp.53-62, 2014. ,
DOI : 10.1161/CIRCHEARTFAILURE.112.969261
Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance, Circulation, vol.122, issue.9, pp.900-909, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.924167
Giant cell myocarditis: still a conundrum. The need for a worldwide registry, European Journal of Heart Failure, vol.373, issue.12, pp.1459-61, 2016. ,
DOI : 10.1056/NEJMoa1406761